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Summary 
 Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection caused by the 
fungus Pneumocystis jirovecii. With the increase in the use of immunosuppressive drugs, 
PJP is increasingly being reported in patients with rheumatoid arthritis (RA). Since PJP 
can be life-threatening, the prevention of the infection is an important challenge in clinical 
practice in RA. Sulfasalazine (SSZ) is one of the traditional disease-modifying anti-
rheumatic drugs. Recently, an experimental study suggested the preventive efficacy of 
SSZ against PJP. However, so far, there has been just one clinical study with a small 
sample size regarding this topic. In this thesis, I investigated the prophylactic effect of 
SSZ by the two types of case-control studies. 
 
Summary of study 1 
Objective: To evaluate the effect of sulfasalazine (SSZ) on the presence of Pneumocystis 
jirovecii (P. jirovecii) in the lungs of rheumatoid arthritis (RA) patients. 
Methods: I retrospectively studied episodes of suspected P. jirovecii pneumonia (PJP) 
which were examined for P. jirovecii with polymerase chain reaction (PCR). I employed 
a test-negative design case-control study; the cases were episodes of suspected PJP that 
were positive for PCR, and the controls were episodes of suspected PJP that were negative 
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for PCR. The odds ratio for the positive PCR result associated with SSZ use was estimated 
by Firth’s logistic regression. 
Results: Between 2003 and 2017, 36 cases and 83 controls were identified. While none 
of the cases received SSZ before the episode, 18 of the controls received the drug. In the 
primary analysis involving all the episodes, SSZ use was negatively associated with PCR 
positivity (adjusted odds ratio, 0.087; confidence interval, <0.001-0.789). The sensitivity 
analysis, excluding those who received PJP prophylaxis, showed the same association as 
the primary analysis (adjusted odds ratio 0.085, 95% CI <0.001-0.790). 
Conclusion: This study demonstrated that SSZ use is associated with the absence of P. 
jirovecii in the lung, suggesting the preventive efficacy of the drug against PJP. 
 
Summary of study 2 
Objectives: To evaluate the prophylactic effect of sulfasalazine against Pneumocystis 
jirovecii pneumonia (PJP) among rheumatoid arthritis (RA) patients. 
Methods: I used a nationwide Japanese multicenter RA database to extract data from 
2005 to 2014. To identify PJP cases, I selected patients hospitalized for PJP and verified 
their diagnosis. Two control groups, one unmatched and the other matched for age, sex, 
glucocorticoid, methotrexate, and tacrolimus dosage, and the use (and type, if used) of 
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biological disease-modifying antirheumatic drug were selected by incidence-density 
sampling. The odds ratios for PJP associated with sulfasalazine use and other clinical 
factors were estimated by exact and standard conditional logistic regression. 
Results: From 18,668 participants, 60 cases, 356 unmatched controls, and 337 matched 
controls were selected. None of the cases received sulfasalazine before PJP onset. A 
comparison of the cases with the unmatched controls showed that sulfasalazine use 
carried a decreased risk of PJP (adjusted odds ratio 0.18, 95% confidence interval 0.00–
0.92). A comparison of the cases and matched controls also showed that sulfasalazine use 
had a decreased risk of PJP (0.08, 0.00–0.36). In an analysis of the cases and unmatched 
controls who did not receive sulfasalazine, an increased risk of PJP was associated with 
lung disease (3.88, 1.89–7.95) and the use of glucocorticoid (5.71, 2.68–12.19), 
methotrexate (5.25, 2.01–13.74), and tumor necrosis factor inhibitors (2.32, 1.10–4.93). 
Conclusions: The results of this nested case-control study demonstrated the preventive 
effect of sulfasalazine against PJP. The results await confirmation by future prospective 
studies. 
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Chapter 1 
Overall background 
 Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection caused by the 
fungus Pneumocystis jirovecii and often affects patients infected with the human 
immunodeficiency virus. With the increase in the use of immunosuppressive drugs, 
especially methotrexate and biological agents, PJP is increasingly being reported in 
patients with rheumatoid arthritis (RA) [1]. Since PJP can be life-threatening, the 
prevention of the infection is an important issue in clinical practice in RA.  
Trimethoprim/sulfamethoxazole has been used as first-line prophylactic agent against PJP 
because of its proven efficacy. Sulfasalazine (SSZ) is one of the traditional disease-
modifying anti-rheumatic drugs and has the anti-inflammatory and antibiotic properties. 
Recently, an experimental study suggested the preventive efficacy of SSZ against PJP [2]. 
If the efficacy is demonstrated in patients with RA, it has important clinical implications. 
However, so far, there has been just one clinical study with a small sample size regarding 
this topic [3]. In this thesis, I investigated the prophylactic effect of SSZ by the two types 
of case-control studies. 
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Chapter 2 
Effect of sulfasalazine use on the presence of Pneumocystis organisms in 
the lung among patients with rheumatoid arthritis: A test-negative 
design case–control study with PCR tests 
(This is the pre-peer reviewed version of the following article: Effect of sulfasalazine use 
on the presence of Pneumocystis organisms in the lung among patients with rheumatoid 
arthritis: A test-negative design case–control study with PCR tests. Takahiro Nunokawa, 
Naoto Yokogawa, Kota Shimada and Shoji Sugii. Mod Rheumatol. 2018 May 3:1-5, 
which has been published in final form at 
https://doi.org/10.1080/14397595.2018.1465647. Underlined parts were added to the pre-
peer reviewed version) 
 
Introduction 
 Pneumocystis jirovecii pneumonia (PJP) is an opportunistic lung infection caused by 
Pneumocystis jirovecii (P. jirovecii) and can be life-threatening. With the increasing use 
of immunosuppressive drugs, particularly tumor necrosis factor (TNF) inhibitors, PJP has 
been reported in patients with rheumatoid arthritis (RA) [1]. Sulfasalazine (SSZ), a 
traditional, synthetic, disease-modifying anti-rheumatic drug (DMARDs), is a conjugate 
4 
 
of the anti-inflammatory 5-aminosalicylic acid and the antibacterial sulfapyridine [2]. 
One experimental animal study reported that SSZ enhances Pneumocystis clearance 
without exacerbating inflammation [3]. However, so far, there has been just one, small, 
case-control study on the topic [4]. Although this study indicated the preventive potential 
of SSZ against PJP, further investigation is needed because of its small sample size of ten 
cases. The case-control study is a practical and efficient design when dealing with a rare 
complication like PJP. However, a misclassification of the outcome status can happen in 
a case-control study in which the outcome is PJP development because making a 
definitive diagnosis of PJP by microscopic detection of the pathogenic organism in 
patients not infected with human immunodeficiency virus (HIV) is difficult due to the 
small organism burden [5]. Therefore, I conducted a case-control study in which the 
outcome was the presence of P. jirovecii in the lung instead of PJP development. 
Furthermore, I employed the test-negative design including only subjects tested with 
polymerase chain reaction (PCR) to confirm the outcome status of all subjects without 
misclassification [6,7].  
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Method 
Study design and participants 
 This retrospective case-control study was conducted at Tokyo Metropolitan Tama 
Medical Center in Japan. The study period was from July 2003 to January 2017. All 
episodes of suspected PJP among patients with RA, whose respiratory specimens were 
tested with PCR for P. jirovecii in any department of the hospital, were enrolled, including 
patients referred to the hospital for acute symptoms. I used the test-negative design to 
evaluate the association between SSZ use and PCR positivity; the cases were all episodes 
of suspected PJP that had a positive PCR result, and the controls were all episodes of 
suspected PJP that had a negative PCR result. In an individual with multiple episodes of 
suspected PJP for which PCR was performed, each episode was counted individually.  
 This study was conducted in accordance with the Declaration of Helsinki and was 
approved by the ethical committee of Tokyo Metropolitan Tama Medical Center.  
 
Data collection 
 The demographic data and clinical information were collected from medical charts 
retrospectively. The enrolled patients were categorized into two age groups: <65 and ≥65 
years. For the detection of P. jirovecii, respiratory specimens, either of induced sputum or 
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bronchoalveolar lavage (BAL) or both, were examined with qualitative PCR analysis at 
SRL Inc. (Tokyo, Japan), and a patient was considered to be positive for P. jirovecii if at 
least one PCR of these specimens was positive. These specimens were also 
microscopically analyzed with Grocott stain. Serum 1,3-β-D-glucan (BDG) was 
measured by Fungitec G test MK or MK Π (Seikagaku, Tokyo, Japan) using their cut-off 
value. Since the remote use of medications for RA and PJP prophylaxis was considered 
not to be associated with PCR positivity, the medications prescribed at the last visit before 
the onset of PJP were collected. Trimethoprim/sulfamethoxazole (TMP/SMX), dapsone, 
atovaquone, pentamidine, and pyrimethamine were considered to be prophylactic drugs 
against PJP. Data on comorbidities, including cases of diabetes mellitus requiring 
treatment with medication, liver cirrhosis, and malignancies, were collected. A 
malignancy without any recurrence for more than five years after the completion of 
treatment was excluded. Estimated glomerular filtration rate was calculated using a 
formula developed by the Japanese Society of Nephrology and was categorized as <60 or 
≥60 ml per min/1.73 m2 [8]. The HIV status of the patients was not collected.  
 
Statistical analysis 
  I determined the difference between the cases and controls using Fisher’s exact test 
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for categorical variables and Student’s t test for continuous variables. A p-value <0.05 
was considered significant. To estimate the unadjusted and adjusted odds ratios (ORs) 
and the corresponding 95% confidence intervals (CIs) for the association between SSZ 
use and the PCR positivity, I used a logistic regression model. On the basis of prior 
knowledge, the possible confounders were identified as age group, lung diseases, 
malignancies, the use of PJP prophylaxis, types of respiratory specimen tested with PCR 
(induced sputum, BAL, or both), and the use of corticosteroid, methotrexate, tacrolimus, 
biological DMARDs (TNF inhibitors, tocilizumab, and abatacept), and 
immunosuppressants (cyclophosphamide, cyclosporine A, and azathioprine) [9–19]. 
Among these variables, those yielding p-values <0.2 in univariate analysis were included 
in the adjusted model of the primary analysis. Coefficients in the logistic regression model 
were estimated using Firth’s penalized likelihood method instead of the maximum 
likelihood method since the issue of quasi-complete separation arose in this data set [20]. 
Specifically, PJP did not develop in any of the RA patients receiving SSZ or PJP 
prophylactics. A sensitivity analysis was performed, limiting the episodes to those without 
PJP prophylaxis. In the sensitivity analysis, unadjusted and adjusted ORs were estimated 
using the same statistical method as the primary analysis, and the adjusted model included 
the covariates used in the primary analysis except the use of PJP prophylaxis. All analyses 
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were done with R (R Foundation for Statistical Computing, Vienna, Austria). 
 
Results 
   During the study period, 119 episodes of suspected PJP in 95 patients with RA were 
tested with PCR. Of all the episodes, 36 (30.3%) had positive and 83 (69.7%) had negative 
PCR results and were included in my analyses as the cases and the controls, respectively. 
There were no missing data in any of the variables. The clinical characteristics of the 
cases and the controls are summarized in Table 1. There were no significant differences 
in sex, age, disease duration or the prevalence of comorbidities. While none of the cases 
received any prophylactic drugs against PJP, 16 of the controls received one drug (14: 
TMP/SMX, 1: atovaquone, and 1: pentamidine). The diagnosis of PJP was made in 31 
(86.1%) cases, but in only eight (9.6%) of the controls. The cases presented with hypoxia, 
fever, and dyspnea and needed O2 supplementation more frequently than the controls. 
PCR was performed for the BAL samples in 30 cases (83.3%) and 47 controls (56.6%). 
Interstitial infiltrate on chest imaging and positive BDG results were more frequent in the 
cases than in the controls (100.0% vs 68.7% and 77.8% vs 34.9%, respectively). All the 
cases and 48 (57.8%) of the controls received antimicrobial treatment for PJP. Mortality 
was similar in the two groups (22.2% vs 19.5%). 
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 The RA medications given to the two groups are shown in Table 2. While none of the 
cases was treated with SSZ, 18 of the controls were treated with SSZ. Methotrexate was 
used significantly more often for the cases than for the controls (75.0% vs 48.2%). The 
use and dosage of other RA medications were similar between the two groups.  
  Based on univariate analysis, the use of PJP prophylaxis, types of respiratory specimen, 
and the use of corticosteroid, methotrexate, and tumor necrosis factor inhibitors were 
introduced into the adjusted model of the primary analysis, and the same variables except 
the use of PJP prophylaxis were introduced into adjusted model of the sensitivity analysis. 
The primary analysis showed that SSZ use was negatively associated with PCR positivity 
in both the unadjusted model (OR 0.049, 95% CI <0.001-0.374) and adjusted model (OR 
0.087, CI <0.001-0.789). The sensitivity analysis involving only those who did not 
receive PJP prophylaxis (all the cases and 67 controls) showed the same association as in 
the primary analysis in both the unadjusted model (OR 0.051, 95% CI <0.001-0.400) and 
adjusted model (OR 0.085, 95% CI <0.001-0.790).  
  As for the predictor variables other than SSZ, in the primary analysis with the adjusted 
model, the use of PJP prophylaxis (OR 0.055, <0.001-0.489) and corticosteroid (OR 
3.572, <1.288-11.313) showed a negative and positive association with PCR positivity, 
respectively, whereas types of respiratory specimen (OR 1.615, <0.875-3.052) and the 
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use of methotrexate (OR 1.575, 0.529-4.939) and tumor necrosis factor inhibitors (OR 
1.393, 0.438-4.479) were not associated with PCR positivity. The result did not 
substantially differ in the sensitivity analysis. 
 
Discussion  
   I hypothesized that SSZ use was associated with the absence of P. jirovecii in the lung 
and tested this hypothesis with a test-negative design case-control study using PCR. In 
both the primary and sensitivity analysis, SSZ use was associated with a negative PCR 
result. This finding corroborates the result of a previous case-control study by Mizushina 
et al., which indicated that SSZ has a preventive effect against PJP [4].  
   Person-to-person airborne transmission is thought to be the most likely route of PJP 
transmission based on previous studies [21–23], and Mori et al. reported an asymptomatic 
carrier state of P. jirovecii and the subsequent development of PJP among RA patients 
receiving low-dose MTX therapy [24]. Wang et al. reported in their experimental study 
using a mouse model of PJP-related immune reconstitution inflammatory syndrome that 
SSZ enhances Pneumocystis clearance from the lung without inducing inflammation by 
accelerating the CD4+ T cell-dependent alveolar macrophage phagocytic response and by 
promoting a TH2-polarized cytokine environment, which alters the macrophage 
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phenotype [3]. These findings suggest that SSZ may prevent RA patients exposed to P. 
jirovecii from pooling the organisms in their lungs and subsequently developing PJP. 
   The gold standard of diagnosis of PJP is the microscopic detection of the organisms 
in respiratory specimens [25]. However, in patients not infected with HIV, the sensitivity 
of the microscopic analysis is low due to a low organism burden [5]. Previous case-control 
studies of PJP among RA patients used diagnostic criteria consisting of the presence of 
either a positive PCR or an increased BDG level, clinical manifestations and radiological 
findings consistent with PJP, and response to standard treatment for PJP [12,26,27]. 
However, since it is difficult to validate the diagnostic criteria due to the lack of a 
reference standard, it is possible that PJP diagnoses based on these criteria may have led 
to the misclassification of the outcome status. Although the specificity of PCR for PJP is 
not high because the test cannot distinguish the disease from Pneumocystis colonization, 
the test is the most appropriate for examining the presence of the organisms in the lungs 
of individuals not infected with HIV regardless of whether the condition is Pneumocystis 
colonization or PJP [28]. In view of the previous reports of PJP development following 
colonization [24,29], my findings of the negative correlation between SSZ use and the 
presence of P. jirovecii in the lung can be seen as corroborating the prophylactic 
effectiveness of SSZ against PJP.  
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   Considering that PJP is a rare complication among RA patients and that the conditions 
for SSZ use change with time in a RA patient, the cohort study is impractical for my 
purposes. The case-control study can circumvent these problems. However, without 
confirmation of laboratory test results for the controls, the traditional case-control study 
may result in misclassification of the outcome status [6]. Therefore, I employed the test-
negative design for my case-control study to reduce the risk of misclassification of the 
outcome status by enrolling only patients with a PCR result [7].    
   My study has several limitations. Since it was a single institution study, my subjects 
cannot be considered as representative of RA patients in Japan. Furthermore, the small 
sample size of my study may have caused the quasi-separation of my data requiring 
special statistical methods. In the logistic regression analysis of data with quasi-separation, 
coefficients cannot be appropriately calculated by maximum likelihood estimation, the 
standard method [30]. Therefore, I used Firth’s penalized likelihood method which allows 
the coefficient to be correctly estimated [20]. Further investigation with a larger sample 
size involving other populations is needed to verify the generalizability of my findings 
and to confirm my results using more straightforward analyses.  
   In conclusion, my test-negative design case-control study using PCR tests revealed 
that SSZ use is associated with the absence of P. jirovecii in the lung of RA patients, 
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suggesting a preventive efficacy of the drug against PJP.   
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Tables  
Table 1. Characteristics of the cases and controls 
 Cases (n=36) Controls (n=83) P value 
Sex, male 8 (22.2) 25 (30.1) 0.504 
Age, year 69.2 ± 7.6 72.2 ± 11.8 0.167 
Age ≥65 years 25 (69.4) 72 (86.7) 0.038 
Disease duration, year 13.7 ± 14.0 11.6 ± 13.7 0.450 
Comorbidities    
  Lung diseases 19 (52.8) 51 (61.4) 0.421 
  Malignancies 1 (2.8) 6 (7.2) 0.673 
  Liver cirrhosis  0 (0.0) 1 (1.2) 1.000 
  Diabetes mellitus 7 (19.4) 20 (24.1) 0.641 
  eGFR <60 mL/min/1.73 m2 13 (36.1) 29 (34.9) 1.000 
PJP prophylaxis use 0 (0.0) 16 (19.3) 0.003 
Clinical diagnosis of the episode   <0.001 
  PJP 31 (86.1) 8 (9.6)  
  Possible PJP 3 (8.3) 19 (22.9)  
  Non-PJP 2 (5.6) 56 (67.5)  
  Hypoxiaa 29 (85.3) 49 (62.8) 0.024 
  O2 supplementation 34 (94.4) 64 (77.1) 0.034 
  Fever (≥37.5°C) 27 (75.0) 41 (51.2) 0.024 
  Dyspnea 32 (88.9) 56 (67.5) 0.022 
  Cough 24 (66.7) 48 (59.3) 0.538 
Type of specimen examined with PCR   0.011 
  Sputum only 6 (16.7) 36 (43.4)  
  Bronchoalveolar lavage fluid only 19 (52.8) 34 (41.0)  
  Both  11 (30.6) 13 (15.7)  
Interstitial infiltrate on chest imaging 36 (100.0) 57 (68.7) <0.001 
1,3-β-D-glucan positive 28 (77.8) 29 (34.9) <0.001 
Antimicrobial treatment for PJP 36 (100.0) 48 (57.8) <0.001 
Outcome of the episode, death 8 (22.2) 17 (19.5) 0.805 
aHypoxia was defined as PaO2 less than 60 mmHg or SpO2 less than 90% in 
ambient air. 
Values are the mean ± SD or the number (%). 
eGFR, estimate glomerular filtration rate; PCR, polymerase chain reaction; 
PJP, Pneumocystis jirovecii pneumonia  
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Table 2. Treatment for rheumatoid arthritis in the cases and controls 
 Cases (n=36) Controls (n=83) P value 
Sulfasalazine use 0 (0.0) 18 (21.7) 0.001 
Sulfasalazine dose (mg/day) 0.0 ± 0.0 210.8 ± 414.1 0.003 
Corticosteroid use 30 (83.3) 56 (67.5) 0.117 
Corticosteroid dose (mg/day) 4.39 ± 3.44 5.65 ± 7.29 0.323 
Methotrexate use 27 (75.0) 40 (48.2) 0.009 
Methotrexate dose (mg/week) 5.97 ± 4.20 6.23 ± 22.01 0.944 
Tacrolimus use 4 (11.1) 9 (10.8) 1.000 
Tacrolimus dose (mg/day) 0.15 ± 0.49 0.19 ± 0.60 0.727 
Bucillamine use 6 (16.7) 10 (12.0) 0.562 
Iguratimod use 1 (2.8) 5 (6.0) 0.666 
Leflunomide use 0 (0.0) 2 (2.4) 1.000 
Tofacitinib use  0 (0.0) 0 (0.0) NA 
Tumor necrosis factor inhibitor use 8 (22.2) 10 (12.0) 0.171 
Tocilizumab use 0 (0.0) 2 (2.4) 1.000 
Abatacept use 0 (0.0) 0 (0.0) NA 
Other DMARD use 2 (5.6) 1 (1.2) 0.217 
Immunosuppressive drug use 1 (2.8) 8 (9.6) 0.274 
Values represent the mean ± SD or the number (%). 
DMARD, disease modified anti-rheumatic-drug; NA, not applicable  
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Table 3. Sulfasalazine use and positive PCR results 
 Primary analysis Sensitivity analysis 
 Odds ratio (95% CI) Odds ratio (95% CI) 
Unadjusted 0.049 (<0.001-0.374) 0.051 (<0.001-0.400) 
Adjusted 0.087 (<0.001-0.789)a  0.085 (<0.001-0.790)b 
aAdjusted for age group, use of prophylaxis against Pneumocystis jirovecii 
pneumonia, types of respiratory specimen, use of corticosteroid, 
methotrexate, and tumor necrosis factor inhibitors. 
bAdjusted for age group, types of respiratory specimen, use of corticosteroid, 
methotrexate, and tumor necrosis factor inhibitors. 
CI, confidence interval 
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Chapter 3  
Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in 
patients with rheumatoid arthritis: A nested case-control study 
(This article has been published at doi: 10.1016/j.semarthrit.2018.05.013. Underlined 
parts were added to the published version) 
 
Introduction 
 Pneumocystis jirovecii pneumonia (PJP) mainly occurs in immunocompromised 
individuals and has also been reported among rheumatoid arthritis (RA) patients, 
especially those receiving low-dose methotrexate (MTX) [1,2] and biological (b) disease-
modifying antirheumatic drugs (DMARDs) [3–8]. PJP incidence among RA patients is 
low but when it does occur, it can be fatal. Regardless of the underlying disease or 
condition, trimethoprim/sulfamethoxazole (TMP/SMX) is recommended as first-line 
prophylaxis for PJP based on its proven efficacy [9,10]. Sulfasalazine (SSZ) is a 
traditional DMARD and consists of anti-inflammatory 5-aminosalicylic acid and anti-
bacterial sulfapyridine. Recently, an experimental study using mice with PJP-related 
immune reconstitution inflammatory syndrome (IRIS) reported that SSZ enhanced fungal 
clearance from the lungs [11]. Furthermore, in a case-control study of PJP and SSZ among 
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RA patients treated with low-dose MTX, no PJP cases received SSZ before PJP onset 
[12]. Although this finding suggested a possible preventive effect of SSZ against PJP, it 
was not conclusive because only ten cases were studied. The present study aimed to 
examine the hypothesis that SSZ lowers PJP incidence among RA patients. To this end, 
I conducted a nested case-control study with unmatched and matched control groups 
using a nationwide, Japanese, multicenter RA database. 
 
Methods 
Data smyce and study design 
 I obtained data from the National Database of Rheumatic Diseases by iR-net in Japan 
(NinJa), a dynamic cohort which commenced in 2002 and is one of the largest registries 
of RA patients in Japan [13]. Patients fulfilling the standard classification criteria for RA 
[14,15] were continually added to the cohort, and their clinical data have been 
accumulated yearly. Hospitalizations in a given year and their reasons, and the RA 
medications prescribed at a single visit arbitrarily chosen by a physician from all the visits 
in the given year (referred to as the data point of the year) were registered. However, part 
of the requisite information for my study, including PJP prophylaxis and co-morbidities, 
was not recorded in NinJa. Furthermore, the follow-up period of patients registered in 
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NinJa varied as did the status of the use of SSZ and other medications over time. 
Therefore, I adopted the nested case-control design with incidence-density sampling. I 
sampled both the unmatched and matched controls for the same cases and analyzed them 
separately (henceforth the unmatched and matched study, respectively) because previous 
reports on PJP risk among RA patients are limited to case reports [1,2,16], post-marketing 
surveillance [5–8], and case-control studies of patients receiving tumor necrosis factor 
(TNF) inhibitors [17–19]. I used the data from 2005 to 2014 because hospitalizations for 
PJP began to be registered after 2005. I excluded patients from hospitals which withdrew 
from NinJa before 2014. This study was conducted in compliance with the Declaration 
of Helsinki principles and was approved by the local ethics committee or institutional 
review board at each participating site. 
 
Case-control selection and additional data collection 
 Initially, patients hospitalized for PJP during the study period were identified from 
NinJa, and then diagnostic information on PJP and data on PJP prophylaxis and co-
morbidities at the last visit before the hospitalization were collected retrospectively by 
reviewing their medical charts (Fig.1). Regarding RA medications, I also retrospectively 
obtained the data from the last outpatient visit prior to hospitalization instead of using the 
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data from NinJa due to the arbitrary time point of the data in this registry. Since the 
diagnoses were made at each participating hospital without standardized diagnostic 
criteria, I verified the diagnostic information and considered as cases those meeting the 
following criteria based on a modification of the definitions from previous studies of PJP 
in RA patients [17–19]: (1) detection of P. jirovecii in respiratory specimens [by 
microscopy with staining or polymerase chain reaction (PCR)] and/or increased level of 
serum 1,3-β-D-glucan(BDG); (2) clinical manifestations (pyrexia, dry cough, or 
dyspnea); (3) diffuse interstitial infiltrate on chest imaging; (4) absence of PJP 
prophylaxis, including TMP/SMX, dapsone, atovaquone, pentamidine, and 
pyrimethamine. An increased level of BDG was defined as a level above the commercial 
cut-off value according to any of following assays: Fungitec G test MK or MK Π; 
Seikagaku, Tokyo, Japan, Wako β-glucan test; Wako Pure Chemical Industries, Tokyo, 
Japan, or β-glucan test MARUHA; Maruha Nichiro Corporation, Tokyo Japan. The 
absence of PJP prophylaxis was added to my definition because those receiving the 
prophylaxis were unlikely to develop PJP, especially when receiving TMP/SMX, a highly 
effective prophylactic [9,10]. I did not include hypoxemia or response to the standard 
treatment for PJP in my definition as previous studies have done because the severity of 
PJP varies widely; while the clinical awareness about PJP among non-human 
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immunodeficiency virus (HIV)-infected individuals has made the diagnosis of this 
condition before the development of respiratory failure more common [20,21], the 
mortality rate of non-HIV-uninfected individuals with PJP in several reports was high 
[22–24]. 
 Next, I identified a risk set for each case from NinJa. The risk set consisted of 
individuals who had been a member of the cohort in the year in which PJP developed in 
the case (the index year) but had not themselves experienced PJP onset until the end of 
the same index year. From the risk set, six individuals were randomly selected for the 
unmatched group. Six other individuals were selected for the matched group by matching 
with the case for age, sex, glucocorticoid (GC), MTX, and tacrolimus (TAC) dosage, and 
the use (and type, if used) of bDMARD (TNF inhibitors, abatacept, or tocilizumab) at the 
data point of the index year recorded in NinJa (Fig.1). I chose these medications as 
possible confounders based on previous reports of PJP among RA patients [1,2, 5–8, 16–
19] and among patients with other conditions [20,25]. Although co-morbidities were 
possible confounders, they could not be included as matching variables because they were 
not recorded in NinJa. Data on PJP prophylaxis and the co-morbidities at the data point 
of the index year for the selected individuals were collected retrospectively by reviewing 
their medical charts (Fig.1). Further, those who had received PJP prophylaxis were 
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excluded from the control group. A control could later become a case and be selected as 
a control for different cases. A subject could also be selected as both unmatched and 
matched controls for the same case. Matching was done using “optmatch” in R 3.3.2 (R 
Foundation for Statistical Computing, Vienna, Austria) [26]. 
 
Predictor variables 
 In addition to matching variables, the two co-morbidities of lung disease and 
malignancy were possible confounders [17,19,20,25]. All analyses used data obtained at 
the last outpatient visit before hospitalization for the cases or the data obtained at the data 
point of the index year for the controls (Fig.1). Age was categorized into two groups: <65 
and ≥65years. A malignancy with no recurrence for more than five years after the 
completion of treatment was excluded. Information on HIV status was not collected from 
the cases or controls. 
 
Statistical analysis 
 Categorical variables between the cases and controls were compared using the Mantel-
Haenszel test with the exact method based on the following strata: the index year in the 
unmatched study and matched set in the matched study. Continuous variables were 
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compared using two-way analysis of variance with the outcome status and the strata as 
factors. A p-value of <0.05 denoted statistical significance. The balance of matching 
variables between the cases and matched controls was assessed using the standardized 
difference. 
 In both the unmatched and matched studies, the adjusted odds ratios (AORs) and 
corresponding confidence intervals (CIs) for PJP associated with SSZ use were estimated 
using exact conditional logistic regression (CLR) with the same stratifications as 
described above because the issue of quasi-complete separation arose in this dataset [27–
29]. Specifically, PJP did not develop in any of the RA patients receiving SSZ. In the 
unmatched study, the odds ratio was adjusted for age group, sex, lung disease, malignancy, 
the use of GC, MTX, and TAC, and the use (and type, if used) of bDMARD. In the 
matched study, the odds ratio was adjusted for lung disease and malignancy. 
 To estimate the PJP risk associated with the variables used in matching, the standard 
CLR relying on the maximum likelihood estimation was performed in the unmatched 
study and included the following variables: age group, sex, lung disease, malignancy, the 
use of GC, MTX, and TAC, and the use (and type, if used) of bDMARD. The analysis 
was limited to those who did not receive SSZ to remove the effect of SSZ on the risk of 
PJP. 
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 The exact CLR was performed using PROC LOGISTIC with EXACT and STRATA 
statements of SAS V.9.4 (SAS Institute, Cary, North Carolina, USA), and the other 
analyses were performed using R 3.3.2. 
 
Sensitivity analysis 
 For sensitivity analysis, I limited the subjects to cases with hypoxemia and response 
to standard treatment for PJP and the corresponding unmatched and matched controls 
when calculating the AORs for SSZ using the exact CLR. 
 
Results 
Study population 
 Fig.2 shows the flow diagram of the study. In the smyce population of 18,668 subjects 
with 64,335 subject-years of observation from 37 hospitals, a total of 73 subjects 
hospitalized for PJP were identified. Seven subjects were excluded due to the lack of 
detailed diagnostic information on PJP, and six were excluded for not fulfilling the 
definition of a case. In two of the former and in all the latter, the information on SSZ use 
before hospitalization was available: none of the subjects had received SSZ. The 
remaining 60 subjects from 23 hospitals were included as cases. For each control group, 
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360 subjects were sampled. Those who received PJP prophylaxis were excluded. The 
remaining 356 subjects from 30 hospitals in the unmatched group and 337 subjects from 
35 hospitals in the matched group were included in my analysis. A subject was selected 
as a non-matched control and a matched control simultaneously for the different cases.  
 
Clinical characteristics of the study participants 
 The clinical and diagnostic information regarding the PJP episodes of the cases is 
summarized in Table1. P. jirovecii was not identified in any of 21 cases whose respiratory 
specimens were microscopically examined. The BDG assay and PCR of the respiratory 
specimens were performed in all and in 37 cases, showing a positivity of 95.0% and 
67.6%, respectively. All cases received standard treatment for PJP. Of these, 55 (91.7%) 
survived and 5 (8.3%) died. 
 Table2 shows the clinical characteristics of the cases and the two control groups 
divided into those that were used for matching and those that were not. There were no 
missing data in any of the variables. In the comparison of the matching variables in the 
unmatched study, older age, the use of GC, MTX, and TNF inhibitors, and a higher 
dosage of GC, MTX, and TAC were significantly associated with PJP. Judging from the 
standardized differences, the matching variables were well-balanced in the matched study 
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except for the dosage of GC. Although the standardized difference in the dosage of GC 
was high at 0.179, the difference in the frequency of GC use was sufficiently low at 0.077. 
Regarding the comparison of the non-matching variables, the cases had lung diseases 
more frequently than the controls both in the unmatched and matched study (41.7 % vs 
15.7% and 20.2%), but there was no significant difference in the existence of 
malignancies. While none of the cases received SSZ, 17.4% of the unmatched controls 
and 12.8% of the matched controls received the drug. In Japan, the maximum approved 
dosage of SSZ is 1.0 g/day. Therefore, most of the doses were less than or equal to 1.0 
g/day both in the unmatched controls (11 with0.5 g/day and 51 with 1 g/day) and in the 
matched controls (fmy with 0.5 g/day,38 with 1 g/day, and one with 1.5 g/day). 
 
Effect of SSZ use on the risk of PJP 
 In the analysis of the unmatched study using the exact CLR, SSZ use had a decreased 
risk of PJP (AOR 0.18, 95% CI 0.00–0.92) after adjusting for age group, sex, lung disease, 
malignancy, the use of GC, MTX, and TAC, and the use (and type, if used) of bDMARD. 
In the analysis of the matched study using the exact CLR, SSZ use also had a decreased 
risk of PJP (AOR 0.08, 95% CI 0.00–0.36) after adjusting for lung disease and 
malignancy (Table3). 
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Risks for PJP 
 The risks for PJP were estimated with the standard CLR analysis of the cases and 294 
unmatched controls not receiving SSZ. The adjusted model included age group, sex, lung 
disease, malignancy, the use of GC, MTX, and TAC, and the use (and type, if used) of 
bDMARD. Lung disease (AOR 3.88, 95% CI 1.89–7.95) and the use of GC (AOR 5.71, 
95% CI 2.68–12.19), MTX (AOR 5.25, 95% CI 2.01–13.74), and TNF inhibitors (AOR 
2.32, 95% CI 1.10–4.93) significantly increased the risk of PJP, and age ≥65years (AOR 
1.83, 95% CI 0.94–3.56) and TAC use (AOR 2.22, 95% CI 0.86–5.71) tended to increase 
the risk of PJP. Sex, malignancy, and the use of tocilizumab and abatacept were not 
associated with the risk of PJP. 
 
Sensitivity analyses 
 When only cases with hypoxemia and a response to standard treatment for PJP (44 
cases) and the corresponding controls (261 unmatched and 250 matched controls) were 
included in an analysis with the exact CLR, the AORs for SSZ use did not substantially 
change either in the unmatched (AOR 0.13, 95% CI 0.00–0.78) or the matched study 
(AOR 0.10, 95% CI 0.00–0.48). 
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Discussion 
 In both the unmatched and matched studies in the current nested case-control analysis, 
SSZ use reduced PJP risk. In the unmatched study, the presence of lung disease and the 
use of GC, MTX, and TNF inhibitors were significant risks for PJP. Age ≥65years and 
TAC use tended to elevate the risk. Based on this fact, my selection of matching variables 
was deemed appropriate. These results supported my hypothesis that SSZ has a 
prophylactic effect against PJP and agreed with the results of the previous single-center 
case-control study by Mizushina et al., which used a smaller sample size than mys [12]. 
 Sulfapyridine was developed as antibiotics in the 1930′s and was combined with 5-
aminosalicylic acid to synthesize an antirheumatic agent with both anti-microbial and 
anti-inflammatory properties because infection was believed to cause RA at that time 
[30,31]. There has been no research on the effect of sulfapyridine on PJP. However, one 
possible explanation for the prophylactic property of SSZ against PJP found in my study 
is the structural commonalities between sulfapyridine and PJP prophylactics. For example, 
both TMP/SMX and sulfapyridine belong to the class of the antimicrobial sulfonamides 
[32]. Furthermore, dapsone, an effective PJP prophylactic for patients who cannot tolerate 
TMP/SMX, is not a sulfonamide but is structurally related to sulfapyridine [33,34]. 
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 Previous studies revealed that PJP in non-HIV-infected individuals produces more 
intense lung inflammation than in HIV patients despite the low organism burden [35,36]. 
In their experimental study using a mouse model of PJP-related IRIS, Wang et al. reported 
that SSZ enhances Pneumocystis clearance without intensifying inflammation by 
accelerating CD4+ T cell-dependent alveolar macrophage phagocytosis and by promoting 
TH-2 polarized cytokine environment leading to alternative macrophage activation [11]. 
From these findings, SSZ can be seen as a reasonable choice for PJP prophylaxis in RA 
patients. 
 My study has several limitations. My results derived from a Japanese cohort. 
Therefore, further investigation involving other population is needed to verify the 
generalizability. A possible misclassification of outcomes is also an important 
consideration. For the case definition of PJP in my study, I modified the definitions used 
in previous studies of PJP in RA patients. The original definition as well as my modified 
version involved using PCR and BDG assays as diagnostic tests [17–19], but neither of 
the definitions has been validated. Furthermore, in my study, while all the cases were 
tested with the BDG assay, 23 of 60 cases (38.3%) were not examined with PCR probably 
because the test is not covered by Japanese national health insurance. Since BDG values 
can be high during infections caused by fungi such as Candida and Aspergillus spp., this 
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test is not specific for PJP. However, a recent meta-analysis evaluating the diagnostic 
accuracy of BDG detection for PJP among those without invasive fungal infections 
showed moderately high specificity at 86.3% [37]. Therefore, my case definition can be 
considered reliable because the clinical manifestations and imaging findings compatible 
with PJP lower the possibility of other fungal infections. Furthermore, all the cases in the 
sensitivity analyses responded to standard treatment for PJP, making the possibility of 
other fungal infections still lower, and the results did not show any significant changes 
from those of the primary analyses. 
 Another limitation is the quasi-complete separation between PJP and SSZ use due to 
the absence of SSZ users among the cases. In this situation, a coefficient of the predictor 
variable in the logistic regression becomes inappropriately infinite by the maximum 
likelihood estimation [38]. There are two ways of dealing with this problem: Firth's 
logistic regression and exact logistic regression [28,39], and I chose the latter because 
only this method was applicable for matched datasets in currently available statistical 
software to the best of my knowledge. This method is similar to Fisher's exact test in that 
it is based on exact conditional inferences and can provide a finite estimate of the 
coefficient even when analyzing data with quasi-complete separation [40]. 
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 It is unlikely that methodological flaws in the study design led to the underestimation 
of SSZ use in the PJP cases and the quasi-complete separation of my data. First, 
measurement errors in SSZ use were unlikely because I obtained the information from 
medical records and clearly specified the time point of the measurement. Second, since 
my study used a large RA cohort without any inclusion or exclusion criteria and thus can 
be considered representative of RA patients in Japan, there is almost no possibility of my 
cases being unrepresentative in terms of SSZ use. Finally, although some of my cases 
may have had TMP/SMX allergy and their physicians might have avoided prescribing 
SSZ due to possible cross-reactivity between SMX and SSZ, which was demonstrated 
only in a small in-vitro study [41], I believe that this possible unmeasured confounder 
was adequately controlled by the matching. Particularly since the matched controls had a 
PJP risk comparable to that of the cases and did not receive TMP/SMX, the possibility of 
TMP/SMX allergy was deemed not to be substantially different between the cases and 
matched controls. Future studies with a larger number of cases will doubtless confirm my 
results with more straightforward analyses. 
 One strength of my study is that the data derived from one of the largest RA databases 
in Japan, allowing us to estimate the precise effect of SSZ on PJP risk by matching the 
important confounders. 
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 The prophylactic efficacy of SSZ against PJP demonstrated by my study can have 
several implications for clinical practice in RA, for example, by promoting the use of SSZ 
for patients with a high risk for PJP or by discmyaging the administration of PJP 
prophylactics to patients already receiving SSZ. My results provide justification for future 
prospective studies. 
 In conclusion, in this nested case-control study based on a nationwide, Japanese, 
multicenter RA database, I was able to demonstrate the preventive effect of SSZ against 
PJP. My promising results should be confirmed by prospective studies. 
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Tables and Figures 
Table 1. Clinical characteristics and diagnostic test results of PJP cases 
Clinical characteristics   
 Pyrexia 55/60 (91.7) 
 Dry cough 42/50 (84.0) 
 Dyspnea 38/57 (66.7) 
 Hypoxemia 49/60 (81.7) 
 Response to standard treatment for PJP 55/60 (91.7) 
 PJP prophylaxis 0/60 (0.0) 
  
Diagnostic tests  
 Microscopic detection of P. jirovecii 0/21 (0.0) 
 Increased serum beta-D glucan 57/60 (95.0) 
 Positive PCR of respiratory specimens for P. jirovecii, 25/37 (67.6) 
 Diffuse interstitial infiltrate on chest imaging 60/60 (100.0) 
PJP, Pneumocystis jirovecii pneumonia; P. jirovecii, Pneumocystis jirovecii; PCR, 
polymerase chain reaction. 
Values represent the number of patients who were positive/number of patients for 
whom data on the clinical manifestations were available or who were examined 
with diagnostic tests (%).  
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Table 2. Clinical characteristics of the cases and the two control groups 
  Unmatched study  Matched study 
  Cases (n=60) Controls 
(n=356) 
p Value  Controls 
(n=337) 
p Value Standerdized 
differencea 
Matching variables        
Age, year 68.0 ± 11.4 63.5 ± 12.9 0.011  67.5 ± 11.1 – 0.045 
Age ≥65 years 40 (66.7) 176 (49.4) 0.017  223 (66.2) – 0.010 
Sex, male  18 (30.0) 78 (21.9) 0.185  95 (28.2) – 0.040 
GC use  48 (80.0) 150 (42.1) <0.001  259 (76.9) – 0.077 
GC dose, mg/dayb 4.15 ± 3.74 1.71 ± 2.62 <0.001  3.55 ± 2.90 – 0.179 
MTX use 53 (88.3) 222 (62.4) <0.001  296 (87.8) – 0.015 
MTX dose, mg/week 7.87 ± 3.99 4.79 ± 4.33 <0.001  7.65 ± 3.94 – 0.055 
TAC use 10 (16.7) 33 (9.3) 0.106  55 (16.3) – 0.009 
TAC dose, mg/day 0.33 ± 0.80 0.15 ± 0.51 0.019  0.32 ± 0.77 – 0.020 
TNF inhibitor usec 19 (31.7) 54 (15.2) 0.003  106 (31.5) – 0.005 
Tocilizumab use 1 (1.7) 11 (3.1) 1.000  6 (1.8) – 0.009 
Abatacept use 3 (5.0) 8 (2.2) 0.202  15 (4.5) – 0.026 
Non-matching variables       
Disease duration, year 14.0 ± 12.2 12.4 ± 11.1 0.328  13.5 ± 11.0 0.776 – 
Lung disease 25 (41.7) 56 (15.7) <0.001  68 (20.2) <0.001 – 
Malignancy 1 (1.7) 19 (5.3) 0.325  11 (3.3) 0.701 – 
SSZ use 0 (0.0) 62 (17.4) <0.001  43 (12.8) 0.001 – 
SSZ dose, mg/day 0 ± 0 159 ± 355 <0.001  123 ± 328 <0.001 – 
Bucillamine use 7 (11.7) 51 (14.3) 0.687  26 (7.7) 0.444 – 
Leflunomide use 0 (0.0) 5 (1.4) 1.000  0 (0.0) NA – 
Tofacitinib use 0 (0.0) 2 (0.6) 1.000  0 (0.0) NA – 
Use of other DMARDd  4 (6.7) 11 (3.1) 0.248  7 (2.1) 0.070 – 
Immunosupressant usee 0 (0.0) 0 (0.0) NA  0 (0.0) NA – 
DMARD, disease-modifying antirheumatic drug; GC, glucocorticoids; MTX, methotrexate; 
NA, not applicable; SD, standard deviation; SSZ, sulfasalazine; TAC, tacrolimus; TNF, tumor 
necrosis factor.  
Each control group was compared with the cases. Values are the mean ± SD or the number 
(%). 
a Absolute values.  
b Prednisolone equivalent. 
c Adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab are included. 
d Mizoribine, iguratimod, actarit, D-penicillamine, auranofin, and lobenzarit are included.  
e Azathioprine, cyclophosphamide, and cyclosporine A are included.  
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Table 3. The use of sulfasalazine and the risk of PJP 
Variables Unmatched studya   Matched studyb 
 Adjusted OR 95% CI  Adjusted OR 95% CI 
  Lower Upper   Lower Upper 
Sulfasalazine 0.18 0.00 0.92  0.08 0.00 0.36 
CI, confidence interval; OR, odds ratio. 
a Adjusted for age group, sex, lung disease, malignancy, use of glucocorticoid, 
methotrexate, and tacrolimus, and use (and type, if used) of biological disease-
modifying antirheumatic drug (tumor necrosis factor inhibitor, abatacept, or 
tocilizumab). 
b Adjusted for lung disease and malignancy. 
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Figure 1. Time points in the assessment of Pneumocystis jirovecii pneumonia 
(PJP) prophylaxis, rheumatoid arthritis (RA) medications, and co-morbidities in 
a case and its corresponding control. NinJa = National Database of Rheumatic 
Diseases by iR-net in Japan 
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Figure 2. Study flow diagram. NinJa = National Database of Rheumatic Diseases 
by iR-net in Japan; PJP = Pneumocystis jirovecii pneumonia. 
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Chapter 4.  
Overall discussion and conclusion 
 In this thesis, the prophylactic efficacy of sulfasalazine (SSZ) against Pneumocystis 
jirovecii pneumonia (PJP) suggested by an experimental study [1] is investigated. Since 
the cohort study is not feasible due to the low incidence of PJP among patients with 
rheumatoid arthritis (RA), I chose the case-control study. Although the gold standard for 
establishing PJP diagnosis is microscopic detection of Pneumocystis organisms in 
respiratory specimens, it is known that Pneumocystis organisms are rarely 
microscopically detected in respiratory specimens from PJP developed in patients with 
not infected with human immunodeficiency virus [2]. Therefore, special consideration for 
the outcome status determination were made in my studies. 
 In Chapter 2, a test-negative design case-control study has been described. In this study, 
the outcome was the presence of P. jirovecii in the lung determined by polymerase chain 
reaction (PCR) instead of PJP development because of the concern regarding the possible 
misclassification of outcome status derived from the difficulty in making the definite 
diagnosis of PJP developed in patients with RA. In the test-negative design case-control 
study, all subjects receive the test for the disease of interest, which still lowers the 
possibility of the outcome status misclassification [3]. This study demonstrated that SSZ 
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use was negatively associated with the presence of P. jirovecii in the lung. This study does 
not directly assess the association between SSZ use and PJP development because PCR 
does not distinguish the colonization of Pneumocystis organisms from PJP. However, 
considering the development of PJP after an asymptomatic carrier state of the organisms 
has been reported in patients with RA, my study suggests that SSZ use suppresses PJP 
incidence [4].  
 In Chapter 3, a nested case-control study using incidence density sampling has been 
described. Although a previous case-control study suggested the prophylactic effect of 
SSZ against PJP, its sample size was too small (ten cases) to be conclusive [5]. I utilized 
one of the largest RA cohort in Japan, the National Database of Rheumatic Diseases by 
iR-net in Japan (NinJa) [6]. By using the cohort as a study base, I sampled more cases 
and controls than the previous study with matching important confounders. The main 
difficulty encountered in this study was confirming the outcome status because the 
definite diagnosis of PJP with microscopic examinations was difficult to make in PJP 
developed in patients with RA. Therefore, I increased the reliability of the outcome 
classification by using the case definition composed of diagnostic test results and clinical 
characteristics. In more than half of the cases, the diagnosis was made based on the 
increased level of serum 1,3-β-D-glucan (BDG). Although BDG is a common cell wall 
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constituent of most fungi and not specific for PJP, the assay has proved to be useful for 
the diagnosis of PJP when the clinical manifestations and imaging findings compatible 
with PJP lower the possibility of other fungal infections [7]. In this study, SSZ users 
showed the reduced risk of PJP. 
 The results of both of the case-control studies conducted by us indicated the preventive 
efficacy of SSZ against PJP. The fact that they enrolled different RA populations and 
setting different outcomes increased the generalizability of their results. My results have 
important implications in clinical practice of RA treatment. For instance, SSZ use is 
advisable for patients with a high risk for PJP, and PJP prophylactics are discmyaged in 
patients already receiving SSZ.  
 In both of the case-control studies, the issue of quasi-complete separation arose 
because none of the cases used SSZ, which precluded the estimation using the maximum 
likelihood method in the logistic regression [8]. I dealt with the issue by means of Firth’s 
logistic regression and exact logistic regression [9,10], which are the currently available 
solutions for this statistical problem. Measurement errors in SSZ use were unlikely 
because the information was obtained from medical records.     
 In NinJa, which is one of the largest RA cohort in Japan and was used as a study base 
in the nested case-control study described in chapter 3, the usage rate of SSZ did not 
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substantially change at approximately 17% throughout the study period (16,6% in 2005 
and 17.3% in 2014). In the nested case-control study, both of the unmatched and matched 
controls were selected from the members of the cohort in the year in which PJP developed 
in the case. Therefore, the observation year of the both control groups was matched with 
the cases. In the test-negative design case-control study, the observation year was not 
matched between the cases and controls and was not included in the adjusted model of 
the multivariate analysis. Although there is a possibility that the observation year was a 
confounder of the study, on the basis of the steady usage rate observed in NinJa, it was 
not deemed to have large effects on the study results.  
 In the study of mouse models of PJP by Bhagwat et al, revealed that innate immunity 
with alternative activation of macrophage is required in the protection against 
Pneumocystis infection [12]. Furthermore, in their experimental study using mice with 
PJP-related immune reconstitution inflammatory syndrome, Wang et al. reported that SSZ 
enhances Pneumocystis clearance without intensifying inflammation by accelerating 
CD4+ T cell-dependent alveolar macrophage phagocytosis and by promoting TH-2 
polarized cytokine environment leading to alternative macrophage activation [1]. These 
findings could explain the underlying mechanism of the prophylactic effect of SSZ 
against PJP shown in my studies. 
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 In my studies, the effect of the predictor variables other than SSZ on the development 
of PJP or PCR positivity was estimated. In the nested case-control study, the use of 
corticosteroid, methotrexate and tumor necrosis factor inhibitors significantly increased 
the risk of PJP. In the test-negative design case-control study, the use of corticosteroid 
was significantly associated with PCR positivity, but the use of methotrexate and tumor 
necrosis factor inhibitors was not associated the positivity. This inconsistency may come 
from the difference in the outcome setting between the two studies or the insufficient 
sample size of the test-negative design case-control study to find the associations. 
 In conclusion, clinical research using case-control studies in this thesis revealed the 
efficacy of SSZ as a prophylactic measure against PJP. This would contribute to the safety 
of tight control treatment strategies for RA using immunosuppressive drugs. My results 
should be confirmed by the prospective cohort  
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